Results 181 to 190 of about 39,537 (208)
Some of the next articles are maybe not open access.
European Review for Medical and Pharmacological Sciences, 2019
OBJECTIVE To explore the effect of long non-coding ribonucleic acid (lncRNA) H19 on the apoptosis of vascular endothelial cells in arteriosclerosis obliterans (ASO) via the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway.
Z-F Li +4 more
semanticscholar +1 more source
OBJECTIVE To explore the effect of long non-coding ribonucleic acid (lncRNA) H19 on the apoptosis of vascular endothelial cells in arteriosclerosis obliterans (ASO) via the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway.
Z-F Li +4 more
semanticscholar +1 more source
SUCCESSFUL THERAPY OF ADVANCED ARTERIOSCLEROSIS OBLITERANS WITH PROSTACYCLIN
The Lancet, 1979Five patients with advanced arteriosclerosis obliterans of the lower extremities, as evidenced by resting pain, ischaemic ulcers, and focal necrosis, received intra-arterial infusions of prostacyclin at doses of 5--10 ng/kg/min for 72 h. Within 2 days of termination of the infusion, pain at rest had disappeared in all patients.
R. Nizankowski +5 more
openaire +3 more sources
[Standardize the endovascular treatment for arteriosclerosis obliterans].
Zhonghua wai ke za zhi [Chinese journal of surgery], 2016Endovascular therapy has become the first-line strategy for most peripheral artery disease cases. Currently, many guidelines recommend endovascular therapy as the first choice for arteriosclerosis obliterans. Recently, drug-eluting stent and drug-coated balloon are available.
Shenming Wang, C Yao
openaire +2 more sources
The Clinical Features and Treatment of Arteriosclerosis Obliterane With Diabetes
Diabetes, 1996The objective of this study was to clarify the differences, if any, in the clinical features between diabetic and nondiabetic patients with arteriosclerosis obliterane (ASO) and to select the optimal treatment for diabetic patients with ASO. The 171 patients with ASO studied were classified into nondiabetic and diabetic groups.
Hiroshi Matsuo +3 more
openaire +3 more sources
Endarteritis obliterans or Arteriosclerosis obliterans?
Pathobiology, 1975H. Jellinek, Zsuzsa Béres, Anna Kádár
openaire +2 more sources
Thromboangiitis Obliterans and Arteriosclerosis Obliterans
Annals of Internal Medicine, 1963James R. Mcpherson +2 more
openaire +3 more sources
ARTERIOSCLEROSIS OBLITERANS; AN EPITOME†
Journal of the American Geriatrics Society, 1959openaire +3 more sources